AFP and neoplasm: Particularly, for patients in BCLC stage C, with HBV infection, without HCV infection, with EHM, without MVI, with tumor size <6 cm or with AFP level <200 ng/ml, lenvatinib significantly prolonged PFS compared with sorafenib.